Biotechnology industries
Viventia Biotech, a biopharmaceutical company developing Armed Antibodies for cancer treatment, presented preclinical research findings in four poster presentations at the 96th American Association for Cancer Research (AACR) Annual Meeting. The company showcased its Stealth Armed Antibody product candidate, VB6-845, and Proxinium, a recombinant immunotoxin for targeting head and neck
Biotechnology industries
Sinovac Biotech Ltd. (SVA) has been experiencing significant growth in the sales of its hepatitis A vaccine, Healive, with domestic Chinese sales reaching approximately US$6.5 million for the year ended December 31, 2004, more than 2 times the sales from 2003. This growth is a testament to the
Biotechnology industries
Amazon Biotech, Inc. (AMZB), a pharmaceutical company developing a potential immunomodulator drug for HIV treatment, has announced its retention of ROI Group Associates, Inc. as its investor relations counsel, marking a significant step as the company prepares to initiate U.S.-based clinical trials. The appointment of ROI Group Associates
Biotechnology industries
Nymox Pharmaceutical Corporation has formed a strategic partnership with KlinLab Ltd., a Czech clinical laboratory company, to make its AlzheimAlert product available to physicians throughout the Czech Republic for the diagnosis of Alzheimer disease. This agreement marks a significant step forward in the distribution of the AlzheimAlert test, which measures
Biotechnology industries
Icoria, Inc. has begun a significant transformation, shifting its focus from agricultural genomics to biomarker-enabled drug discovery. This shift, following the acquisition of certain agricultural genomics assets by Monsanto Company, led to the resignation of three long-serving board members: Robert M. Goodman, PhD, Susan Harlander, PhD, and Michael Summers. As
Biotechnology industries
ID Biomedical Corporation, a Canadian biotechnology company, has achieved a significant milestone in its efforts to bring a new influenza vaccine to the market. The company has completed the enrollment of 1,000 healthy adults for a clinical trial of its Fluviral vaccine, exceeding its original target of 300 subjects.
Biotechnology industries
Cell Genesys, Inc., a biotechnology company, has announced the appointment of Robert J. Dow as senior vice president, medical affairs. Dow brings over 20 years of biopharmaceutical experience, having previously held senior executive positions at companies such as Biolitec Pharma, Ltd., Quantanova, and Scotia Holdings, plc. He holds a BSc
Biotechnology industries
GPC Biotech, AG, a biotech company focusing on developing anticancer drugs, reported financial results for the fourth quarter and fiscal year ended December 31, 2004. The company's revenues decreased 41% to €12.6 million in 2004 compared to €21.6 million in 2003, primarily due to the expiration
Biotechnology industries
Cephalon, Inc. (CEPH) has reported a significant increase in revenue for 2004, with sales reaching $980.4 million, a 43% increase from 2003. The company's three lead products have posted outstanding sales increases, positioning Cephalon for significant growth ahead. The company's chairman and CEO, Frank Baldino
Biotechnology industries
The Toronto Stock Exchange plans to enhance its competitiveness in the global market by targeting Chinese companies looking for capital, according to Richard Nesbitt, its chief executive. The exchange will focus on sectors such as energy, mining, and biotechnology, which are already strong areas for the TSX. This move comes
Biotechnology industries
Amgen, Inc., has provided holders of its Liquid Yield Option Notes due 2032 (Zero Coupon-Senior) the opportunity to surrender their notes for purchase at a price of $738.68 per $1,000 of principal amount. The Put Option, which expires on March 1, 2005, allows each holder to require Amgen
Biotechnology industries
Icoria, Inc. has received a U.S. patent for their methods in identifying inhibitors of asparagine synthase as antibiotics, a novel gene target for antibiotic development in a biochemical pathway by which fungi produce asparagine. This patent covers methods that potentially increase the probability of discovering fungicides that affect this
